Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
New information on the bronchiectasis patient priorities website aims to keep you informed about antibiotics, anti-inflammatory drugs (drugs that reduce swelling) and other medicines in development.
Drugs cannot be used to treat people in Europe until they have gone through clinical trials. Clinical trials are research studies that test whether new drugs are safe and effective in people.
This new information (which we’re calling ‘Drugs in development’) was prompted by the bronchiectasis patient advisory group (PAG) and has been developed by bronchiectasis medical experts in Europe. It has also been reviewed by members of our bronchiectasis PAG. In the future, ‘Drugs in development’ will be reviewed regularly to make sure that it is up to date.
You can find out about some of the different ways you can get involved in research and clinical trials on the ‘Drugs in development’ web page.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79